Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Fig. 2

Dasatinib, and not bosutinib, treatment ameliorates arthritis symptoms. Clinical (a) and histopathological (b) arthritis scores showing the response of Tg197 animals treated with dasatinib (30 mg/Kg) or bosutinib (75 mg/Kg) in comparison to Infliximab (10 mg/Kg) treatment. (** p-value < 0.01; *** p-value ≤ 0.0001). All data are shown as mean ± SEM and all comparisons were made against vehicle

Back to article page